PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media286942ArticlesСтатьиResearch ArticleDVOYNAYa BLOKADA HER2-PETsEPTOPA - NOVOE NAPRAVLENIE V LEChENII RAKA MOLOChNOY ZhELEZY S GIPEREKSPRESSIEY HER2ДВОЙНАЯ БЛОКАДА HER2-PEЦEПTOPA - НОВОЕ НАПРАВЛЕНИЕ В ЛЕЧЕНИИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ С ГИПЕРЭКСПРЕССИЕЙ HER2Gan'shinaI. PГаньшинаИ. ПLubennikovaE. VЛубенниковаЕ. ВZhukovaL. GЖуковаЛ. Г

к.м.н., ведущий научный сотрудник отделения химиотерапии и комбинированных методов лечения

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва20042014218NO8 (2014)№8 (2014)757926022023Copyright ©; 2014, Bionika MediaCopyright ©; 2014, ООО «Бионика Медиа»2014Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/286942

With the advent of trastuzumab, vector of the prognostic significance of tumor marker has been changed for the first time in oncology practice - patients with HER2-positive tumors, previously considered as the most unfavorable, currently have the best prognosis. HER2 blockade strategy has been so successful that now it is the most extensively studying direction in the treatment of breast cancer (BC). The combination of pertuzumab, trastuzumab and docetaxel as first-line therapy for metastatic breast cancer has increased the progression-free survival by 6 months, and the use of trastuzumab as a neoadjuvant therapy has allowed to achieve complete pathological remission in 63 % of cases. Trastuzumab in combination with lapatinib in patients with progression on trastuzumab-containing regimens, has allowed to increase overall survival by 4.5 months; trastuzumab in the neoadjuvant therapy in combination with paclitaxel has allowed to achieve complete pathological remission in 51 % of cases.

С появлением трастузумаба впервые в онкологической практике удалось изменить вектор прогностической значимости опухолевого маркера - больные HER2-позитивными опухолями, ранее считавшимися наиболее неблагоприятными, в настоящее время имеют наилучший прогноз. Стратегия блокады HER2 оказалась настолько успешной, что в настоящее время именно это направление наиболее активно исследуется при раке молочной железы (РМЖ). Комбинация пертузумаба, трастузумаба и доцетаксела в первой линии терапии метастатического РМЖ позволила увеличить выживаемость без прогрессирования на 6 месяцев, а в неоадъювантном режиме - добиться частоты достижения полной морфологической ремиссии в 63 % случаев. Трастузумаб в комбинации с лапатинибом позволил увеличить общую выживаемость больных, имеющих прогрессирование на трастузумаб-содержащих режимах, на 4,5 месяца, а в неоадъювантном режиме в комбинации с паклитакселом - добиться частоты полной морфологической ремиссии в 51 % случаев.

trastuzumabpertuzumablapatinibdual blockadeтрастузумабпертузумаблапатинибдвойная блокадаBlackwell K.L., Burstein H.J., Storniolo A.M., et al. Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study. 2012; 30(21 ): 2585-92.Gianni L., Llad A., Bianchi G., et al. Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J. Clin. Oncol. 2010; 28: 1131-37.Allison D.E., Ng C., Derynck M.K., et al. Pharmacokinetics (PK) of pertuzumab (rhuM-Ab 2C4) in phase II studies of ovarian, breast, prostate, and lung cancers. ASCO Meeting Abstracts. 2005; 23: 2532.Baselga 4.J., Gelmon K.A., Verma S., et al. Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. J. Clin. Oncol. 2010; 28: 1138-44.Baselga J., Cortes J., Kim S.-B., et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. The New England journal of medicine. 2012; 366(2).Ellis P.A., Barrios C.H., Im Y., et al. MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC). ASCO Meeting Abstracts. 2011; 29: TPS102.Swain S.M., Kim S.B., et al. Pertuzumab, trastuzumab and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA STUDY): overall survival results from a randomized, double-blind, placebo-controlled, phase 3 study. April 18,2013. www.thelancet.com/oncology Published onlineRimawi M.F., Poole C.J., et al. Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study PERTAIN). Journal of Clinical Oncology, 2012 ASCO Annual Meeting Abstracts. 2012; 30(15): TPS654.Gianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer randomized controlled superiority trial with a parallel HER-negative cohort. 2010; 375. www.thelancet.com.Gianni L., Semiglazov V., Manikhas G., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patient with HER-2 positive locally advanced breast cancer(the NOAH trial): a randomized controlled superiority trial with a parallel HER2-negative cohort. 2010; 375. www.thelancet.comGianni L., Eiermann W., Semiglazov V., et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomized controlled superiority trial with a parallel HER2-negative control. Lancet Oncol. 2014; 15(Issue 6): 640-47.Gianni L., Pienkowski T., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicenter, open-label, phase 2 trial. 2012; 13. www.thelancet.com/oncologySchenewweiss A., Chia S., Hickish T., et al. Perrtuzumab plus trastuzumab in combination with standart neoadjuvant anthracycline-containing or concurrent with anthracycline-free chemotherapy regimens in patients with HER-2 positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals Oncol. 2013; 24: 2278-84.